Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,883 shares of the company’s stock after buying an additional 10,482 shares during the period. Edgestream Partners L.P. owned 0.09% of Apellis Pharmaceuticals worth $3,506,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new stake in Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. Capital Performance Advisors LLP bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $56,000. KBC Group NV grew its stake in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Finally, US Bancorp DE grew its stake in shares of Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after purchasing an additional 1,327 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO James George Chopas sold 1,096 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the sale, the chief accounting officer now directly owns 48,138 shares of the company’s stock, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Caroline Baumal sold 2,816 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now directly owns 55,560 shares of the company’s stock, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,934 shares of company stock valued at $1,950,261. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ APLS opened at $25.04 on Friday. The business has a fifty day simple moving average of $29.08 and a 200-day simple moving average of $31.07. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -12.33 and a beta of 0.93. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12 month low of $23.77 and a 12 month high of $63.07.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.73) EPS. Sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Royal Bank of Canada decreased their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research note on Monday, March 3rd. Wedbush decreased their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.53.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).